<DOC>
	<DOCNO>NCT01374750</DOCNO>
	<brief_summary>The purpose study evaluate anti-tumor effect sirolimus-based immunosuppressive regimen patient follow live donor liver transplantation hepatocellular carcinoma exceed Milan criterion respect recurrence-free survival .</brief_summary>
	<brief_title>Efficacy Sirolimus In Liver Transplantation Hepatocellular Carcinoma ( HCC )</brief_title>
	<detailed_description>The Milan criterion adopt western country decease donor allocation identify subgroup candidate hepatocellular carcinoma ( HCC ) transplant result similar patient transplant end- stage liver disease without HCC . There debate involve expand indication beyond Milan criterion live donor liver transplantation ( LDLT ) . Some transplant surgeon argue despite poor result , LDLT advance HCC may justify , since donor voluntarily accept risk donor hepatectomy dedicate graft HCC patient , may otherwise effective treatment . Especially , Korea live donor liver transplantation ( LDLT ) commonly perform , expansion Milan criterion inevitable . Sirolimus macrolide antibiotic produce Streptomyces hygroscopic demonstrate potent immunosuppressive activity number study . The efficacy sirolimus immunosuppressive demonstrate randomized clinical trial kidney transplantation . The use sirolimus liver transplantation rapidly increase standpoint reduce conventional calcineurin inhibitor toxicity . Sirolimus emerge effective alternative patient renal insufficiency relate calcineurin inhibitor toxicity . In recent study , difference observe respect rejection major complications.The use sirolimus transplant patient associate dose-dependent increase serum cholesterol triglyceride may require treatment . In recent study liver transplant recipient use sirolimus part primary immunosuppressive regimen , occurrence acute cellular rejection relatively low . There data suggest sirolimus associate hepatic artery thrombosis . Numerous current study show sirolimus may inhibitory effect development cancer . Immunosuppressive agent antineoplastic activity inherently attractive set liver transplantation HCC . If sirolimus show degree anti-tumor effect transplant recipient advance HCC , indication LDLT advance HCC expanded.Our hypothesis sirolimus based-regimen improve HCC recurrence free survival . If sirolimus-based protocol show well recurrence free survival , indication LDLT HCC expand . LDLT one best treatment modality advance HCC . The patient advance HCC benefit liver transplantation .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Inclusion Criteria : 1 . Age ≥ 18 yr weight ≥ 40 kg . 2 . Histologically proven HCC exceed Milan criterion randomization , regardless prior therapy 3 . Signed date write informed consent 4 . Lack relevant exclusion criterion 5 . Women childbearing potential must negative qualitative serum pregnancy test Investigational agent administration must agree use medically acceptable method contraception treatment period study . Exclusion Criteria : 1 . Multiple organ recipient 2 . Deceased donor liver transplant 3 . Known hypersensitivity Simulect® , sirolimus , tacrolimus , cyclosporine , MMF derivatives 4 . Hyperlipidemia refractory optimal medical management ( cholesterol &gt; 300 mg/dl ; Triglycerides &gt; 350 mg/dl ) 5 . Evidence significant local systemic infection time randomization . 6 . Known HIVpositive patient 7 . Women childbearing potential willing take contraception 8 . Patients nonHCC malignancy within past 5 year , exclude successfully treat squamous cell carcinoma basal cell carcinoma skin 9 . Patients HCC involvement major branch ( portal vein , hepatic vein , etc . ) hepatic blood vessel pathological evaluation c.f . Major branch define first second order branch ( e.g . In case portal vein , right leave portal vein , right anterior posterior portal vein , leave medial lateral portal vein ) 10 . Patients evidence extrahepatic HCC metastasis 11 . Patients psychological , familial , sociologic geographic condition potentially hamper compliance study protocol followup schedule 12 . Use investigational drug treatment 4 week enrol study 24month treatment period . 13 . Hepatic artery stenosis occlusion diagnose Doppler 14 . Patients severe renal insufficiency randomization time point ( GFR &lt; 40mL/min , Proteinuria &gt; 800mg/24hrs ) 15 . Patients severe leucopenia and/or thrombocytopenia refractory medical treatment ( ANC &lt; 500/ul , platelet &lt; 30K/ul )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>